

# NEUROTHERAPEUTICS SEMINAR SERIES



TEXAS A&M HEALTH  
Institute of Pharmacology  
and Neurotherapeutics

## BARDA: Development of Medical Countermeasures to Address CBRN Threats

**Monday, September 26, 2022**

HSC Bryan Campus/MREB2 Room 1403

12:00 - 1:00 PM

**Lunch Provided --- Q&A Session & Networking Opportunity**

Join via Zoom  Meeting ID: 942 5772 9124 Passcode: 052206

### Dr. Judith Wolfe Laney

*Chief Chemical Medical Countermeasures Branch, CBRN Division, BARDA*

Dr. Judy Laney is the Chief of the Chemical MCM branch within the Division of Chemical, Biological, Radiological, and Nuclear Countermeasures, Biomedical Advanced Research and Development Authority (BARDA). The mission of the BARDA Chemical MCM program is to improve health outcomes for victims of exposure to chemical warfare agents, TICs, and TIMs through improved response, improved standards of care, and improved therapeutic interventions. The program currently supports the development of more than fifteen MCMs and enabling technologies across five priority threat areas, with an emphasis on repurposing clinically used medications to treat the effects of chemical exposure.

Prior to joining BARDA in 2011, Dr. Laney was the Science and Technology Manager for Chemical Medical Countermeasures in the Joint Science and Technology Office for Chemical and Biological Defense at the Defense Threat Reduction Agency (JSTO-CBD/DTRA). At DTRA, she managed an early discovery program for novel prophylactics and therapeutics targeted against chemical warfare agents, including catalytic bioscavengers, acetylcholinesterase reactivators, and neuroprotectants. She has also studied the threat from chemical and biological terrorism and supported the Chemical Countermeasures portfolio at the US Department of Homeland Security.

Dr. Laney received her BS degree from the Univ. of Maryland and a MA degree from Harvard Univ., both in Organic Chemistry. She earned her Ph.D. in Bio-Organic Chemistry from MIT, where she studied molecular recognition and designed catalytic systems. She holds five US patents for rationally-designed enzyme inhibitors.



**Dr. Judy Laney**

Host: Dr. Samba Reddy  
sambareddy@tamu.edu

For more info, contact Dr. Sreevidhya Ramakrishnan at [sreevidh@tamu.edu](mailto:sreevidh@tamu.edu)

IPN Website:

